Cubist Systematic Strategies LLC Makes New Investment in Haemonetics Corporation $HAE

Key Points

• Cubist Systematic Strategies LLC has invested approximately $8.21 million in Haemonetics Corporation, acquiring 129,259 shares valued at 0.26% of the company.
• Institutional investors and hedge funds now own 99.67% of Haemonetics' stock, indicating a strong interest from large financial entities.
• Haemonetics recently reported earnings of $1.10 per share, surpassing estimates and setting FY 2026 guidance between $4.70 to $5.00 EPS.

Cubist Systematic Strategies LLC purchased a new position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 129,259 shares of the medical instruments supplier's stock, valued at approximately $8,214,000. Cubist Systematic Strategies LLC owned about 0.26% of Haemonetics as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Quarry LP raised its position in shares of Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after purchasing an additional 192 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in Haemonetics during the 1st quarter valued at about $65,000. KBC Group NV grew its stake in Haemonetics by 19.9% during the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after acquiring an additional 401 shares in the last quarter. AlphaQuest LLC grew its stake in Haemonetics by 71.5% during the 1st quarter. AlphaQuest LLC now owns 3,140 shares of the medical instruments supplier's stock valued at $200,000 after acquiring an additional 1,309 shares in the last quarter. Finally, Vise Technologies Inc. grew its stake in Haemonetics by 8.7% during the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after acquiring an additional 225 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Stock Down 0.1%

Shares of HAE traded down $0.05 during midday trading on Monday, reaching $54.34. The stock had a trading volume of 138,853 shares, compared to its average volume of 806,737. Haemonetics Corporation has a 1-year low of $50.68 and a 1-year high of $94.99. The company's fifty day simple moving average is $66.04 and its two-hundred day simple moving average is $65.77. The company has a market cap of $2.62 billion, a price-to-earnings ratio of 16.61, a PEG ratio of 1.00 and a beta of 0.39. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping the consensus estimate of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. During the same period last year, the business earned $1.02 EPS. Haemonetics's revenue for the quarter was down 4.4% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Equities research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on HAE shares. Mizuho dropped their price objective on shares of Haemonetics from $90.00 to $70.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Citigroup raised shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price objective for the company in a research note on Wednesday, July 9th. Barrington Research dropped their price objective on shares of Haemonetics from $95.00 to $86.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Baird R W raised shares of Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. Finally, Robert W. Baird assumed coverage on shares of Haemonetics in a research note on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $85.18.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.